PDE-5 inhibitors found safe, efficacious in male LUTS
Phosphodiesterase type-5 inhibitors are safe and effective, alone or in combination with alpha-blockers, against lower urinary tract symptoms (LUTS) secondary to BPH, according to a systematic review and meta-analysis.
Phosphodiesterase type-5 inhibitors are safe and effective, alone or in combination with alpha-blockers, against lower urinary tract symptoms (LUTS) secondary to BPH, according to a systematic review and meta-analysis.
Moreover, the two-drug combination improves maximum flow rate compared to alpha-blockers alone. Younger men with lower body mass index and severe LUTS are the best candidates for PDE-5 inhibitor treatment, the review showed.
First author Mauro Gacci, MD, of the University of Florence Careggi Hospital in Florence, Italy, and co-authors from Europe and the U.S. identified 508 studies in an electronic search, retrieving 106 for more detailed evaluation and finally including 12 for this review. In seven studies, patients with LUTS/BPH were treated with PDE-5 inhibitors alone. The other five examined the effects of PDE-5 inhibitors with an alpha-blocker.
The PDE-5 inhibitor monotherapy studies included 3,214 randomized patients, of whom 2,250 received PDE-5 inhibitors (83.5% completed the study) and 964 received placebo (90.2% completed the study). The combination therapy studies included 278 patients, of whom 107 received alpha-blockers only (92.5% completed the study) and 109 received PDE-5 inhibitors plus alpha-blockers (94.5% completed the study).
A 2.8-point reduction in International Prostate Symptom Score was noted in patients treated with PDE-5 inhibitor therapy alone and a reduction of 1.8 in patients who had received combination therapy, Dr. Gacci reported. International Index of Erectile Function score improved 5.5 points in PDE-5 inhibitor patients and 3.6 points in PDE-5 inhibitor/alpha-blocker patients. Dr. Gacci noted no change in Qmax in patients receiving PDE-5 inhibitor therapy alone and an improvement of 1.5 in patients treated with PDE-5 inhibitors/alpha blockers.
The meta-analysis demonstrated that age, BMI, and baseline IPSS score were the main determinants for PDE-5 inhibitor outcomes.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Dr. Goudelocke outlines stand-up urgency in patients with OAB
April 18th 2024"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.
